Results 11 to 20 of about 82,196 (246)

Postoperative respiratory depression in patients on sublingual buprenorphine: a retrospective cohort study for comparison between postoperative continuation and discontinuation of buprenorphine

open access: yesJA Clinical Reports, 2022
Background We tested the hypothesis that patients who continued buprenorphine postoperatively experience postoperative respiratory depression less frequently than those who discontinued buprenorphine.
Ryu Komatsu   +5 more
doaj   +1 more source

Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation

open access: yesHarm Reduction Journal, 2022
Background Syringe services programs (SSPs) hold promise for providing buprenorphine treatment access to people with opioid use disorder (OUD) who are reluctant to seek care elsewhere.
Andrea Jakubowski   +8 more
doaj   +1 more source

Buprenorphine reduces methamphetamine intake and drug seeking behavior via activating nociceptin/orphanin FQ peptide receptor in rats

open access: yesFrontiers in Psychiatry, 2022
Buprenorphine, which has been approved for the treatment of opioid dependence, reduces cocaine consumption by co-activating μ-opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors. However, the role of buprenorphine in methamphetamine (METH)
Fangmin Wang   +11 more
doaj   +1 more source

Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France

open access: yesHarm Reduction Journal, 2021
Background Some people do not benefit from oral administration of opioid agonist treatment, and an intravenous (IV) formulation may be more suitable. Our objective was to evaluate the willingness of people who regularly inject sublingual buprenorphine to
Salim Mezaache   +6 more
doaj   +1 more source

Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants

open access: yesAddiction Science & Clinical Practice, 2022
Background Medications for opioid use disorder (MOUDs), including methadone, buprenorphine, and naltrexone, decrease mortality and morbidity for people with opioid use disorder (OUD).
Barbara Andraka-Christou   +4 more
doaj   +1 more source

Buprenorphine Waiver Attitudes Among Primary Care Providers

open access: yesJournal of Primary Care & Community Health, 2022
Background: Despite efforts to improve access to Medications for Opioid Use Disorder (MOUD), such as buprenorphine, the number of opioid overdoses in the United States continues to rise.
Benjamin Lai   +2 more
doaj   +1 more source

Single high-dose buprenorphine for opioid craving during withdrawal. [PDF]

open access: yes, 2018
BackgroundOpioid use disorder is one of the most prevalent addiction problems worldwide. Buprenorphine is used as a medication to treat this disorder, but in countries where buprenorphine is unavailable in combination with naloxone, diversion can be a ...
Ahmadi, Jamshid   +3 more
core   +2 more sources

Emergency Department Buprenorphine Quality Improvement and Emergency Physician Knowledge, Attitudes, and Self-Efficacy

open access: yesWestern Journal of Emergency Medicine, 2023
Objective: Buprenorphine is an evidence-based treatment for opioid use disorder that is underused in the emergency department (ED). In this study we evaluated changes in emergency physician knowledge, confidence, and self-efficacy regarding buprenorphine
Michelle L. Myles   +5 more
doaj   +1 more source

The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. [PDF]

open access: yes, 2010
This prospective patient-preference study examined the effectiveness in practice of methadone versus buprenorphine maintenance treatment and the beliefs of subjects regarding these drugs. A total of 361 opiate-dependent individuals (89% of those eligible,
Holland, R   +5 more
core   +1 more source

Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use

open access: yesAddiction Science & Clinical Practice, 2023
Background We use a novel, longitudinal approach to describe average time spent in opioid use disorder (OUD) cascade of care stages for people with HIV (PWH) and with OUD, incorporating four definitions of treatment retention.
Jarratt D. Pytell   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy